Egret Technologies congratulates its client Dexcom, a leader in continuous glucose monitoring, on the announcement today that the U.S. Food and Drug Administration has approved its eagerly anticipated new continuous glucose monitoring system, the Dexcom G4™ PLATINUM.

Clinical trials report up to approximately 19 percent improvement in overall accuracy for the Dexcom G4™ PLATINUM compared to the Seven Plus, and approximately a 30 percent improvement in accuracy in the hypoglycemia range (i.e., when blood glucose is less than 70mg/dl). The overall accuracy and ease of use for the Dexcom G4™ PLATINUM sets a new standard for commercially available CGMs, making the Dexcom G4™ PLATINUM the most-advanced CGM system available.

The Dexcom G4™ PLATINUM offers not only outstanding accuracy and performance, but many new capabilities, including:

• Longest transmission range, enabling improved patient flexibility and convenience
• A smaller, discrete profile that fits busy lifestyles
• A first-of-its-kind color LCD display for easy viewing
• Customizable alerts with specific tones
• “Hypo alert” setting at 55 mg/dl that provides an increased level of safety – a feature that no other device provides.

Egret Technologies was an integral part of the G4™ PLATINUM Team with responsibility for the design of the G4™ PLATINUM CGM Wireless Transmitter.